Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer
Abstract
OBJECTIVE: The objective of this research was to examine the influence of metformin on both prognosis and adverse reactions in patients who have undergone radical cystectomy (RC) and subsequently received adjuvant gemcitabine and cisplatin (GC) chemotherapy for muscle-invasive bladder cancer (MIBC). METHODS: A retrospective evaluation was performed on data from 243 patients who had undergone RC followed by adjuvant GC chemotherapy at the Affiliated Hospital of Xuzhou Medical University, Xuzhou First People’s Hospital, and Xuzhou Third People’s Hospital during the period from April 2014 to April 2024. The subjects were categorized into three categories based on metformin usage: non-diabetic (No DM), type 2 diabetic with metformin use (DM + Metformin), and type 2 diabetic without metformin use (DM-Metformin). Clinical and pathological characteristics were compiled and subjected to analysis. Progression-free survival (PFS) was assessed utilizing the Kaplan–Meier technique, while Cox proportional hazards models were employed for multivariable analysis. RESULTS: Among the 243 patients, diabetes was present in 68 individuals, of whom 51 were administered metformin. Pairwise comparisons revealed that diabetic patients receiving metformin exhibited significantly higher 3-year PFS rates compared to both diabetic patients not using metformin (23.6% vs. 7.2%, p = 0.007) and non-diabetic patients (23.6% vs. 13.4%, p = 0.034). In the multivariable analysis, metformin use was…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 243 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.